Study Title and Description
Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial.
Key Questions Addressed
|3||Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?|
Primary Publication Information
|Title||Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial.|
|Author||Lufkin EG., Whitaker MD., Nickelsen T., Argueta R., Caplan RH., Knickerbocker RK., Riggs BL.|
|Country||Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, Minnesota 55905, USA.|
Pubmed ID: 9797484
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-4
Results & Comparisons
No Results found.